NIAID forms network to tackle potentially fatal reaction to smallpox vaccine
by Paul Williams
National Institute of Allergy and Infectious Diseases
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), today launched the Atopic Dermatitis and Vaccinia Network (ADVN), a nationwide research group that seeks to reduce the risk of eczema vaccinatum (EV), a severe and potentially deadly complication of smallpox immunization. EV occurs almost exclusively in people with a history of atopic dermatitis (AD), a chronic, itchy skin condition commonly referred to as eczema.
While uncommon, EV can develop when AD patients are given the smallpox vaccine or come into close personal contact with people who recently received the vaccine. If untreated, EV can kill between 1 to 6 percent of those affected. In children younger than 2 years of age, EV has been estimated to kill up to 30 percent.
"Millions of Americans have a history of atopic dermatitis," says Anthony S. Fauci, M.D., director of NIAID. "Launching this network is an important step toward our goal of helping to protect everyone against the smallpox virus without the risk of life-threatening complications."
"Previous studies suggest that both innate and adaptive immunity are impaired in patients with atopic dermatitis, but the specific defects that increase the likelihood of eczema vaccinatum have yet to be explained," says Daniel Rotrosen, M.D., director of NIAID's Division of Allergy, Immunology and Transplantation. "The information generated by this network will improve our understanding of the immune responses of these patients and should greatly influence the design of a safer smallpox vaccine."
The ADVN comprises three integrated components: a clinical studies consortium, an animal studies consortium and a statistical and data coordinating center.
The ADVN Clinical Studies Consortium will, among other activities, seek to understand why people with AD have such severe reactions to smallpox vaccine by evaluating their immune responses after natural exposure to less harmful skin viruses such as herpes simplex. The ADVN Animal Studies Consortium will establish animal models of AD and investigate their immune responses to vaccinia--the virus used in smallpox vaccine--and other skin viruses such as varicella, which causes chickenpox and shingles. The ADVN Statistical and Data Coordinating Center will support these clinical and animal studies by analyzing research data, coordinating trials and regulatory activities, and developing and maintaining a registry of AD patients. The six institutions in the ADVN Clinical Studies Consortium and the principal investigator at each are:
National Jewish Medical and Research Center, Donald Leung, M.D., Ph.D.
Oregon Health and Science University, Jon Hanifin, M.D.
Children's Hospital Boston, Lynda Schneider, M.D.
University of California at San Diego, Richard Gallo, M.D., Ph.D.
Johns Hopkins Asthma and Allergy Center, Lisa Beck, M.D.
University of Bonn, Germany, Thomas Bieber, M.D., Ph.D.
The five institutions in the ADVN Animal Studies Consortium and the principal investigators at each are:
Children's Hospital Boston, Raif Geha, M.D., and Hans Oettgen, M.D., Ph.D
National Jewish Medical and Research Center, Donald Leung, M.D., Ph.D., and Erwin Gelfand, M.D.
Harvard Skin Diseases Research Center, Thomas Kupper, M.D., and Robert Fuhlbridge, M.D.
University of Illinois at Chicago, Lawrence Chan, M.D.
La Jolla Institute for Allergy and Immunology, Toshiaki Kawakami, M.D., Ph.D.
The ADVN Statistical and Data Coordinating Center will be operated by Rho Federal Systems Division. The principal investigator is Susan Lieff, Ph.D.
National Institute of Allergy and Infectious Diseases
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), today launched the Atopic Dermatitis and Vaccinia Network (ADVN), a nationwide research group that seeks to reduce the risk of eczema vaccinatum (EV), a severe and potentially deadly complication of smallpox immunization. EV occurs almost exclusively in people with a history of atopic dermatitis (AD), a chronic, itchy skin condition commonly referred to as eczema.
While uncommon, EV can develop when AD patients are given the smallpox vaccine or come into close personal contact with people who recently received the vaccine. If untreated, EV can kill between 1 to 6 percent of those affected. In children younger than 2 years of age, EV has been estimated to kill up to 30 percent.
"Millions of Americans have a history of atopic dermatitis," says Anthony S. Fauci, M.D., director of NIAID. "Launching this network is an important step toward our goal of helping to protect everyone against the smallpox virus without the risk of life-threatening complications."
"Previous studies suggest that both innate and adaptive immunity are impaired in patients with atopic dermatitis, but the specific defects that increase the likelihood of eczema vaccinatum have yet to be explained," says Daniel Rotrosen, M.D., director of NIAID's Division of Allergy, Immunology and Transplantation. "The information generated by this network will improve our understanding of the immune responses of these patients and should greatly influence the design of a safer smallpox vaccine."
The ADVN comprises three integrated components: a clinical studies consortium, an animal studies consortium and a statistical and data coordinating center.
The ADVN Clinical Studies Consortium will, among other activities, seek to understand why people with AD have such severe reactions to smallpox vaccine by evaluating their immune responses after natural exposure to less harmful skin viruses such as herpes simplex. The ADVN Animal Studies Consortium will establish animal models of AD and investigate their immune responses to vaccinia--the virus used in smallpox vaccine--and other skin viruses such as varicella, which causes chickenpox and shingles. The ADVN Statistical and Data Coordinating Center will support these clinical and animal studies by analyzing research data, coordinating trials and regulatory activities, and developing and maintaining a registry of AD patients. The six institutions in the ADVN Clinical Studies Consortium and the principal investigator at each are:
National Jewish Medical and Research Center, Donald Leung, M.D., Ph.D.
Oregon Health and Science University, Jon Hanifin, M.D.
Children's Hospital Boston, Lynda Schneider, M.D.
University of California at San Diego, Richard Gallo, M.D., Ph.D.
Johns Hopkins Asthma and Allergy Center, Lisa Beck, M.D.
University of Bonn, Germany, Thomas Bieber, M.D., Ph.D.
The five institutions in the ADVN Animal Studies Consortium and the principal investigators at each are:
Children's Hospital Boston, Raif Geha, M.D., and Hans Oettgen, M.D., Ph.D
National Jewish Medical and Research Center, Donald Leung, M.D., Ph.D., and Erwin Gelfand, M.D.
Harvard Skin Diseases Research Center, Thomas Kupper, M.D., and Robert Fuhlbridge, M.D.
University of Illinois at Chicago, Lawrence Chan, M.D.
La Jolla Institute for Allergy and Immunology, Toshiaki Kawakami, M.D., Ph.D.
The ADVN Statistical and Data Coordinating Center will be operated by Rho Federal Systems Division. The principal investigator is Susan Lieff, Ph.D.
